Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

Single Rising Dose Study of MK-1708 in Healthy Participants Ended

2023-506946-21-00 Amyotrophic lateral sclerosis and Alzheimer’s disease 2023-10-24
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer Ended

2022-502125-17-00 Advanced solid tumors 2023-10-16
SAD and MAD study of VES001 Ended

2023-505847-38-00 Frontotemporal dementia (FTD) 2023-10-11
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess Ho… Ended

2023-505684-36-00 Healthy Volunteers 2023-10-09
A controlled, randomized, first-in-human study of AP31969 investigating single and multiple ascending doses and the effect of food in health… Ended

2023-505424-57-00 Atrial Fibrillation (cardiac arrhythmia) 2023-10-04
Study of GS-4528 for Adults With Solid Tumors Ended

2022-502070-16-00 Solid Tumors 2023-10-02
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors Ended

2022-502867-39-00 Advanced solid tumors including non-small cell lung can 2023-09-29
A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended

2022-502850-14-00 gastroesophageal junction 2023-09-25
A double-blind, randomized, placebo-controlled, dose-escalating Phase I trial to determine the safety, pharmacokinetic parameters, and clini… Ended

2023-504671-24-00 Men and women infertility 2023-09-22
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zosurabalpin following Intravenous Administration in Healthy Partic… Ended

2023-505411-20-00 There is no medical condition being investigated. This 2023-09-20
A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene … Ended

2024-518451-39-00 Adrenomyeloneuropathy 2023-09-19
A study to learn how safe the study treatment BAY2701250 is, how it affects the body and how it moves into, through and out of the body in h… Ended

2023-503368-18-00 Pulmonary hypertension due to left heart disease 2023-09-14
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PARALLEL AND PLACEBO-CONTROLLED SINGLE AND MULTIPLE ASCENDING DOSE TRIAL INVESTIGATING SAFETY, TOLERAB… Ended

2023-505280-36-00 Erectile dysfunction 2023-08-25
A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and… Ended

2023-504450-35-00 Plaque psoriasis 2023-08-21
A three part randomized, double-blind, placebo-controlled, parallel group SAD and MD clinical study to evaluate the safety, tolerability and… Ended

2023-507203-55-00 Pseudomonas colonization 2023-08-21
A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 … Ended

2022-502866-25-00 Sepsis associated disseminated intravascular coagulatio 2023-08-18
A study of the safety of the new investigational drug CVN293 in healthy volunteers, and how CVN293 is taken up and processed by the human bo… Ended

2023-506114-49-00 Neurodegenerative disorders 2023-08-15
A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, P… Ended

2023-503866-22-00 metabolic bone diseases 2023-08-11
A Study to Learn About the Study Medicine Called PF-07293893 in Healthy Adults, and How Different Doses of Study Medicine are Tolerated and … Ended

2023-504921-37-00 heart failure with preserved ejection fraction (HFpEF) 2023-08-04
MK-7480 Single Ascending Dose Study in Healthy Participants Ended

2023-505138-88-00 Non-alcoholic steatohepatitis 2023-08-03
A study of HFB200603 as a single agent and in combination with Tislelizumab in patients with advanced solid tumors Ended

2022-502891-22-00 Advanced Solid Tumors 2023-08-02
A study in healthy men to test how different doses of BI 3000202 are tolerated and how food influences the amount of BI 3000202 in the blood Ended

2022-502424-43-00 Healthy volunteer trial 2023-07-25
SAD and MAD of VENT-02 in healthy volunteers Ended

2023-505546-26-00 Neuroinflammatory and neurodegenerative diseases 2023-07-21
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOr… Ended

2024-514225-30-00 Acromegalia 2023-07-11